National Grid completes electricity tunnel breakthrough 49 days ahead of schedule

- Tunnel boring machine Caroline has completed her 2.2km drive beneath the River Thames, marking the end of tunnelling on National Grid’s Grain to Tilbury project

- Breakthrough was achieved 49 days ahead schedule, following exceptional tunnelling performance

- The milestone supports National Grid's work to strengthen the electricity network and connect cleaner, home-grown energy to homes and businesses

National Grid has reached a major milestone on its Grain to Tilbury project, part of The Great Grid Upgrade, after tunnel boring machine (TBM) Caroline successfully completed her breakthrough under the River Thames on Sunday 27 September after excavating a new 2.2km high-voltage electricity cable tunnel between Tilbury in Essex and Gravesend in Kent.

Caroline completed the final stage of her journey underwater, with the reception shaft intentionally flooded to balance pressure between the shaft and surrounding chalk ground and reduce the risk of groundwater entering the shaft during the final stage of tunnelling.

With more than 10,000 concrete tunnel segments installed to create the tunnel lining, and nearly 1,700 tunnel rings constructed, the breakthrough marks the completion of the project's tunnelling phase. The milestone was achieved 49 days ahead of the original programme following an exceptional tunnelling performance by teams working on the 2.2km drive beneath the River Thames.

The achievement was supported by close collaboration between National Grid, delivery partner Ferrovial BEMO JV, design partner Mott MacDonald and tunnelling specialist Herrenknecht. Careful planning, favourable ground conditions, and the proven performance of the tunnel boring machine all contributed to the early breakthrough, alongside well-coordinated logistics that kept tunnel segments continuously delivered to the TBM, while a dedicated separation plant reliably processed excavated material uninterrupted and efficiently.

Combined with the expertise of engineers, operators and construction teams, Caroline maintained strong progress throughout the tunnelling phase. In the most productive month, she advanced 926 metres and installed 712 tunnel lining rings. At peak performance, the machine advanced 229 metres in a single week, while its best daily output saw 41 metres excavated and 31 tunnel rings installed in just 24 hours.

Digital design tools and connected TBM data also supported delivery by improving visibility, quality assurance and decision-making. An integrated underwater telescopic camera allowed inspections to be carried out remotely, reducing the need for personnel intervention and supporting safe working practices.

Mark Farmer, Project Director, National Grid, said:

"The breakthrough of TBM Caroline is a fantastic achievement and a major milestone for the Grain to Tilbury project."

"Completing this tunnel drive ahead of schedule is a testament to the expertise, dedication and collaboration of our teams and supply chain partners. Everyone involved has worked together to deliver an exceptional performance safely and efficiently, helping us reach this important milestone sooner than anticipated."

"This project will play a critical role in strengthening the electricity network and supporting Britain's future energy needs as demand for cleaner electricity continues to grow."

Borja Trashorras, Project Director, Ferrovial BEMO JV, said:

“Reaching breakthrough ahead of schedule is the result of excellent planning, strong engineering expertise and outstanding collaboration across the project team.”

“The combination of diligent planning, efficient logistics, innovative tunnelling technology and a highly skilled workforce enabled us to achieve consistently strong performance throughout the drive. We are extremely proud of this achievement and of everyone who contributed to making it possible.”

Ulrich Schaffhauser, Member of the Board, Herrenknecht AG, said:

“The fast completion of the cable tunnel beneath the River Thames shows the value of effectively coordinating all project components, technologies, and services. With our product and service portfolio, we were able to deliver not only the TBM tailored to the operating conditions, but also the corresponding separation equipment and tunnel logistics for continuous tunnelling performance.”

"This breakthrough demonstrates what can be achieved when advanced tunnelling technology, efficient project execution and strong teamwork come together. We congratulate the entire project team on reaching the breakthrough safely and successfully."

The shaft at Gravesend was intentionally flooded before breakthrough. Due to the local chalk ground conditions, the shaft had to be flooded, creating a balanced hydrostatic pressure between the shaft and the surrounding ground. This significantly reduced the risk of groundwater flowing into the shaft as the machine broke through.

Following the breakthrough, activities will continue to allow TBM Caroline to advance beyond the shaft wall and reach its final position, enabling the remaining ring-segment construction works to be completed.

Dewatering of the shaft started in September and will continue through October. Once complete, the TBM will be lifted, before being disassembled as the project progresses into its next phase of construction.

Live working moves a step closer after National Grid secures innovation funding

Four National Grid projects have secured more than £5 million through the next stage of Ofgem's Strategic Innovation Fund (SIF) programme, including a project that could reintroduce live working on the UK transmission network for the first time in a generation – supporting faster delivery and reducing system costs.

The projects span both the Discovery and Beta phases of the SIF programme, which supports the development and testing of new technologies and approaches to help transform Great Britain’s energy networks.

National Grid Electricity Transmission (NGET) has been awarded £4,947,031 for the DEsign for Live Line Technology Acceleration (DELLTA) three-year Beta phase project.

Maintenance on transmission assets is typically carried out during planned outages, when circuits are taken out of service, which can be costly and difficult to schedule. By enabling maintenance on live assets, DELLTA could reduce outages, maintain network capacity and help accelerate vital grid reinforcement.

It follows a successful Alpha phase and will see the project continue to develop techniques that could enable maintenance to be safely carried out on high-voltage transmission networks while they remain energised.

DELLTA is being led by National Grid Electricity Transmission in partnership with Frazer-Nash Consultancy, The University of Manchester, Allied Insulators, The University of Liverpool and SSEN Transmission as well as the Budapest University of Technology and Economics to learn global best practice.

During its Alpha phase, the project successfully demonstrated a proposed live insulator replacement method on a de-energised network. The new funding will support a three-year Beta phase which will further develop the advanced equipment, procedures and training required for live working.

The project's main focus will be the live replacement of overhead line insulators, but will also explore other potential live working uses. It will see a team being trained in carrying out live working, with the project culminating in a demonstration of techniques and technologies on NGET’s network.

The overall ambition of the DELLTA project is for live working to be a business-as-usual tool for the transmission network.

NGET is also a partner on the Quantum optimisation for future gas network design project, which is being led by National Gas and has been awarded £616,558 of SIF Alpha phase funding.

The project will look to develop a quantum computing inspired optimisation approach to improve outage planning in gas transmission, but also has the potential to be applied across electricity networks, supporting whole-system planning and improving efficiency.

Neil McClymont, Head of Innovation at National Grid Electricity Transmission, said:

“As demand for electricity grows, innovation is essential in helping us futureproof the network. These projects will help us explore new technologies, techniques and approaches that can support a more flexible and resilient network.

“The DELLTA project is particularly exciting as it has the potential to transform how we work by developing the equipment and techniques needed to safely carry out maintenance on the transmission network while assets remain in service, reducing the need for planned outages and minimising associated costs.”

The projects are funded through the Strategic Innovation Fund, an Ofgem programme managed in partnership with Innovate UK.

National Grid Electricity Distribution (NGED) has been awarded almost £550,000 for three projects.

DISPATCH, which stands for Data-Integrated Systems for Power Transmission and Community Heat, will investigate how the siting of data centres could have spin-off benefits. It will examine if medium-size centres can provide low-temperature waste heat to benefit households with extra needs, and look at the potential of sharing flexibility service income with heat networks.

SOS Racer (Security of Supply - Revised Approach to Consider Embedded Resources) will assess how battery storage, solar and wind farms could provide additional assurance that the electricity system can be secure at times of peak demand. It will examine how distributed demand-side flexibility can also inform future resilience, planning and market frameworks.

The third NGED funding award is for the Innovation Delivery Group (IDG) charter discovery project looking at decentralised system balancing.

The IDG, which is chaired by National Grid Electricity Distribution’s DSO managing director Cathy McClay, with Rebecca Beresford of the National Energy System Operator (NESO) as vice chair, will set out clear delivery pathways and identify gaps in the products, services and capabilities needed for decentralised system balancing. These findings will help inform decisions on which future innovation projects could best address those gaps.

Emily Spearman, Director of Innovation at National Grid Electricity Distribution, said:

“These projects highlight how innovation can help tackle some of the biggest challenges facing the future energy system, from strengthening security of supply and enabling decentralised system balancing to creating wider benefits for customers and communities.

“By working with partners across the sector, we can turn new ideas into practical solutions that support a more resilient, flexible and affordable electricity network.”

Arirang TV, Teams Up with Shindong, Kwon Hyuk-soo and Yujeong to Showcase Gyeongbuk's "Flavors and Charms" to the World!

- A single journey through the food, travel and culture of Mungyeong, Pohang, Gyeongju and Andong…showcasing Gyeongbuk's appeal to global audiences

「K-FOOD: Gyeongbuk Edition」

Premieres on Arirang TV on October 14 at 9:00 a.m. (KST)

Airs every Wednesday at 9:00 a.m. (KST) for four weeks.

SEOUL, South Korea, Oct. 11, 2026 /PRNewswire/ -- Arirang TV (CEO Kim Tae-jeong) will air "K-FOOD: Gyeongbuk Edition," a global promotional program that showcases the diverse culinary and tourism offerings of Gyeongsangbuk-do to audiences around the world, every Wednesday at 9:00 a.m. (KST) for four weeks starting October 14.

Set in Mungyeong, Pohang, Gyeongju and Andong, the series is a "taste road variety" show that weaves regional signature dishes, tourist attractions, history and culture, and hands-on experiences into a single travel story. The cast members form a "Taste Crew," sampling local food for themselves and enjoying a range of tours and activities, while turning photos and videos shot on their travels into social media content to share Gyeongbuk's appeal with global viewers.

Kwon Hyuk-soo, Yujeong and Harin make up Team A, while Shindong, Lim Do-hwa and Seungwoo form Team B.

Episode 1: Mungyeong edition spotlights the Mungyeong Coal Museum, Jinnamgyoban, rail bike and Mungyeong Saejae, presenting the region's industrial heritage and natural scenery alongside signature local foods such as spicy freshwater fish stew and Yakdol pork.

Episode 2: Pohang edition visits Yeongildae Beach, Jukdo Market, SpaceWalk and Homigot, introducing Pohang's signature dishes — snow crab and mulhoe (chilled raw fish soup) — together with the scenery of the East Sea and hands-on tourism.

Episode 3: Gyeongju edition explores the Gyeongju National Museum, Gyochon Village, House of the Gyeongju Choi Clan, Luge World and Donggung Palace and Wolji Pond, shedding light on Silla's history and traditional culture as well as a new side of Gyeongju that younger visitors can enjoy.

Episode 4: Andong edition takes place in Hahoe Folk Village, Sinse-dong Mural Village and Andong Old Market, capturing local dishes such as heotjesatbap, gan-godeungeo (salted mackerel) and Andong jjimdak, together with traditional culture and contemporary travel content.

A distinguishing feature of the program is that it does not focus on the food alone: it also showcases the history, people, nature, tourism and experiences of the regions where that food was born. The series is further designed so that global viewers can experience Gyeongbuk in a more approachable way, by showing the cast creating their own social media content and taking on a dance challenge.

Through this program, Arirang TV plans to extend the world's growing interest in K-FOOD to regional tourism in Gyeongbuk and — by promoting the food, history, nature and cultural appeal of Mungyeong, Pohang, Gyeongju and Andong overseas — to contribute to enhancing Gyeongsangbuk-do's global tourism brand value and revitalizing regional tourism.

Broadcast Information

- Arirang TV: K-FOOD: Gyeongbuk Edition

- Youtube: https://www.youtube.com/@BeMyKorea

SOURCE Arirang TV

Share this article

FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) Highlights Faraday Future Announcement: This Week's Investor Weekly Report from YT Jia Rescheduled to October 14; FFR and FFAI to Host Joint New Product Launch Event on October 14

- FFAI has announced that this week's Investor Weekly Report from FF Founder and Global CEO YT Jia has been rescheduled to October 14.

- FFR and FFAI will host a joint new product launch event on October 14, featuring FF Nova, FF Nova Mini, the EAI Education Ecosystem Brain and Curriculum Skills 2.0, and the FF Nova Developer Reinforcement Learning Platform.

- FFAI has announced that it will co-host an AIAA LA Seminar with AIAA at FFAI headquarters to address Frontier Technology in Engineering and Academia. More than 50 scholars and professors from leading universities and the AI field were invited to the event.

LOS ANGELES, Oct. 11, 2026 /PRNewswire/ -- FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR), a U.S.-based Embodied AI ("EAI") robotics company that has proposed to acquire Faraday Future Intelligent Electric Inc.'s (NASDAQ: FFAI) EAI Robotics business, today highlighted FFAI's announcement that this week's Investor Weekly Report from Faraday Future ("FF") Founder and Global CEO YT Jia has been rescheduled to October 14.

Additionally, FFR and FFAI will host a joint new product launch event on October 14, 2026, featuring four major launches focused on embodied AI robotics, Physical AI education, and developer enablement.

The event will feature FF Nova, FF's first embodied AI humanoid robot designed for developers and educational institutions, through an exclusive, invitation-only launch.

FFAI has also announced that FF will introduce FF Nova Mini, a humanoid robot designed for foundational Physical AI education, along with the EAI Education Ecosystem Brain and Curriculum Skills 2.0.

In addition, FF will launch the FF Nova Developer Reinforcement Learning Platform and open exclusive early access to the developer community.

The full video will be available for viewing at https://www.ff.com/us/ on October 15 at 5:00 p.m. PDT.

About FF EAI Robotics Ecosystem Inc.

FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) is a U.S.-based Embodied AI (EAI) robotics company that is in the process of acquiring the FF EAI Robotics business. Upon completion of the acquisition, the Company will focus on the research and development, manufacturing, commercialization, and deployment of intelligent robotic technologies, products, and industry solutions.

The Company is committed to building a "Four-Core Full-Stack" AI ecosystem covering the full lifecycle of robotics, consisting of EAI Brain & Developer Platform, EAI Devices, Industry Productivity Solutions, and EAI Data Factory. Guided by the technology and product philosophy of "One Brain, Multi-forms, Multi-capabilities," the Company aims to empower humanoid, biomimetic, and other robotic form factors through a unified EAI Brain, while continuously expanding their multi-task and multi-scenario capabilities. The ecosystem is designed to support the full robotics lifecycle, including R&D, deployment, data collection and training, operations, and commercial applications.

The FF EAI Robotics business has already achieved commercial deliveries of humanoid and biomimetic robotic products. Through its multi-form-factor robotic products, EAI technology platform, closed-loop data capabilities, and industry solutions, the business continues to advance the scaled adoption of robotics across real-world applications. The Company also operates RoboShare, a robot-sharing and services platform designed to connect robotic assets, service capabilities, customer demand, and ecosystem partners, further strengthening its robotics commercialization and service ecosystem.

ABOUT FARADAY FUTURE

Founded in 2014, Faraday Future (FF) is a U.S.-based Physical AI ecosystem company dedicated to reshaping the future of robotics and mobility solutions through AI innovation and technologies. FF focuses on two major product strategies within the Embodied AI (EAI) robotics business: EAI humanoid and bionic robots, and EAI automotive-focused robots. By building a "Four-Core Full-Stack AI" ecosystem of EAI Brain and Developer Platform, EAI Devices, Industry Productivity Solutions and EAI Data Factory, FF aims to create an evolutionary flywheel: scaled device delivery, data collection and training, continuous evolution of the EAI Brain, stronger product capability, and even larger-scale delivery and deployment. Through this flywheel, FF seeks to maximize its commercial value and lead to the advancement of Physical AI. For more information, please visit Faraday Future's official website: https://www.ff.com/

FFR Forward-Looking Statements

This communication, including any presentation, press release, investor materials or other document of which it forms a part (this "Communication"), contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, as amended, and other securities laws, regarding FF EAI Robotics Ecosystem Inc. ("FFR," the "Company," "us," "our," or "we") and our industry. All statements, whether written or oral, other than statements of historical fact, including any financial projections and any statements regarding future events, our strategy, our transition to robotics operations, our plans for RoboShare, our digital asset disposition plans, the proposed acquisition of the FF EAI Robotics business, the projections referenced in this communication, our name and ticker change, any related financing, and the anticipated benefits and timing of the foregoing, our objectives, expectations, or anticipated actions or results, are forward-looking statements. You can often identify forward-looking statements by words such as "may," "might," "will," "shall," "should," "expects," "plans," "anticipates," "could," "intends," "targets," "projects," "contemplates," "believes," "estimates," "predicts," "potential," "goal," "objective," "seeks," "likely," or "continue," or the negative of these terms or other similar expressions; the absence of these words does not mean a statement is not forward-looking. These statements reflect our current expectations and projections about future events as of the date of this Communication and are necessarily based on estimates and assumptions that, while considered reasonable by management, are inherently uncertain. FFR can give no assurance that such forward-looking statements or financial projections will prove to be correct.

Actual results may differ materially from those expressed or implied by these forward-looking statements as a result of numerous risks and uncertainties, both general and specific, including, but not limited to:

The proposed transaction. The term sheet is non-binding and may not result in definitive agreements; the proposed transaction may not be approved by our special committee of independent directors, our stockholders or applicable regulators, and may not be completed on the terms described or at all; the conditions to closing and the parties' ability to satisfy them; the timing of the transaction and the costs of pursuing it; the issuance of a substantial number of shares as consideration and the resulting dilution; the proposed special stock dividend and our ability to declare and pay it; the fact that the counterparty is our controlling stockholder and the conflicts of interest inherent in the transaction; our dependence on the counterparty for transition, supply and support following any closing; the scope and enforceability of the proposed non-competition and governance arrangements; the consequences of the transaction under Nasdaq listing rules, including the possibility that we must satisfy initial listing requirements in connection with a change of control or change in the nature of our business; our ability to integrate and operate the acquired business; and the risk that the acquired business performs differently than anticipated.

Projections. The projections referenced in this communication were prepared by FFAI management for the FF EAI Robotics business on a standalone basis and do not reflect our existing business, transaction-related expenses or the combined company. We have not independently verified them or adopted them as guidance. They were not prepared with a view toward public disclosure or toward compliance with the published guidelines of the Securities and Exchange Commission or the American Institute of Certified Public Accountants regarding prospective financial information, and no independent registered public accounting firm has examined, compiled or performed any procedures with respect to them, and none expresses an opinion or any other form of assurance with respect to them. The projections reflect estimates and assumptions that are inherently uncertain and subject to change, including through due diligence and the review of our special committee and its financial advisor. Actual results are likely to differ, and may differ materially.

Liquidity, capital and going concern. Our limited cash and liquidity position and our history of operating losses and negative operating cash flow; substantial doubt regarding our ability to continue as a going concern, as described in our periodic reports; our need to obtain additional financing on acceptable terms or at all, and the substantial dilution to existing stockholders that additional financing may cause, including any financing completed in connection with the proposed transaction, which may not be completed or may be on less favorable terms than anticipated; our ability to fund operations pending and following the disposition of our digital asset positions; and our ability to satisfy the continued listing requirements of The Nasdaq Stock Market, including stockholders' equity, minimum bid price and other applicable standards.

Scage Future Provides Business Update on Deliveries, Technology Portfolio and Growth Initiatives; Initiates Regular Investor Communication

NANJING, China, Oct. 11, 2026 /PRNewswire/ -- Scage Future (Nasdaq: SCAG) ("Scage" or the "Company"), a provider of new energy and zero-emission heavy-duty commercial vehicles and e-fuel solutions, today provided an update on its commercial progress, technology portfolio and growth initiatives, together with a recap of its Nasdaq listing compliance status.

As previously disclosed, the Company is not currently in compliance with certain Nasdaq continued listing requirements. On June 11, 2026, the Company received notice from Nasdaq regarding the minimum bid price requirement, with a compliance period through December 8, 2026. On August 27, 2026, the Company received notices regarding the Market Value of Listed Securities requirement and the Market Value of Publicly Held Shares requirement, in each case with a compliance period through February 23, 2027. The Company has also received notice regarding the composition of its audit committee, with a remediation period through December 22, 2026. The Company's American depositary shares continue to trade on The Nasdaq Global Market under the symbol "SCAG", and none of these notifications has resulted in the immediate delisting or suspension of the Company's securities. There can be no assurance that the Company will regain compliance with any of these requirements within the applicable compliance periods, and a failure to do so could result in the delisting of the Company's American depositary shares from Nasdaq. The information in this announcement should be read together with the Company's disclosure regarding these matters.

Since completing its business combination and listing in June 2025, the Company has focused on engineering, product certification and customer delivery and has not issued periodic operating updates. With this release, the Company is launching a program of periodic operating updates.

Commercial Progress

As of June 30, 2026, the Company had delivered a cumulative total of 203 vehicles since inception, comprising 154 autonomous port tractors, 47 Galaxy II plug-in hybrid trucks and 2 other vehicles. During the fiscal year ended June 30, 2026, the Company delivered 78 autonomous port tractors and 40 Galaxy II units and sold 466 vehicle energy storage systems to external customers. In the six months ended June 30, 2026, the Company received new orders for 43 vehicle units with an aggregate contract value of approximately RMB 26.86 million.

Delivered vehicles are in commercial operation across port, logistics, concentrated solar power and agricultural applications. The Company has a five-year capacity assurance framework agreement, entered into in July 2025, with Shanghai Westwell Technology Co., Ltd. ("Westwell"). In its prospectus filed with the Shenzhen Stock Exchange, Westwell identifies Nanjing Scage Automobile Technology Co., Ltd. ("Nanjing Scage"), an operating subsidiary of the Company in the People's Republic of China (the "PRC"), as its largest raw material supplier in each of 2023, 2024 and 2025, and as one of its principal suppliers of vehicle chassis, frames and related components and of outsourced assembly. Westwell also states that its business has expanded to 30 countries and regions.

Technology and Intellectual Property

As of June 30, 2026, Nanjing Scage held 17 pending patent applications and 96 granted patents in the PRC, comprising 9 pending invention patent applications and 7 granted invention patents, 8 pending utility model applications and 87 granted utility model patents, and 2 granted design patents. Outside the PRC, Nanjing Scage is a joint registered owner of one granted patent: Canadian Patent No. CA 3154425, covering a drive apparatus and drive method for hybrid trucks, granted in April 2026. The Company's electric drive axle technology is protected under Chinese invention patent ZL202210355042.1, covering a multi-in-one integrated commercial vehicle electric drive axle and granted in December 2025, and under Chinese utility model patents ZL202322430283.0 and ZL202122739062.2, each held by Nanjing Scage. Nanjing Scage also holds 10 registered software copyrights and 19 registered trademarks, of which 15 are registered in China and 4 outside China (three in Thailand and one in the European Union).

Thirty-four of the Company's 85 employees, or approximately 40%, are engaged in research and development. The Company operates a 1,234-square-meter research, development and testing facility in Nanjing. The Company's core technologies, including its intelligently distributed hybrid power ("IDHP") system, solid oxide electrolysis cell ("SOEC") hydrogen production and L4 intelligent drive-by-wire chassis, are developed by its operating subsidiaries in the PRC. As of June 30, 2026, the Company held granted Chinese patents covering its integrated dual-motor heavy-truck electric drive axle, an SOEC test apparatus and its drive-by-wire chassis, and had three pending invention patent applications relating to SOEC technology.

Manufacturing and Quality Systems

Nanjing Scage is recorded as a powertrain manufacturer for plug-in hybrid heavy-truck models listed in the Announcement of Road Motor Vehicle Manufacturers and Products published by the Ministry of Industry and Information Technology of the PRC. Vehicle assembly is carried out with established original equipment manufacturers, including Anhui Wuchuan Feicai. The Company also holds ISO 9001, ISO 14001 and ISO 45001 certifications and is recognized as a High and New Technology Enterprise (Certificate No. GR202432005986, issued November 2024).

Partnerships

In July 2026, the Company entered into a comprehensive strategic cooperation agreement with Dongfeng Liuzhou Motor Co., Ltd. covering brand cooperation, joint product development and overseas market cooperation.

Growth Initiatives

The Company is developing three initiatives alongside its existing vehicle business. First, in December 2025, Scage (Hong Kong) Limited, a subsidiary of the Company, entered into an investment cooperation agreement with the Anci District People's Government of Langfang, Hebei Province, for an integrated renewable power, hydrogen production and heavy-truck manufacturing project. Under the agreement, the project comprises three elements: (i) a heavy-truck and core component manufacturing base together with headquarters and research and development facilities, (ii) a hydrogen energy network project, and (iii) a wind-power green electricity and energy storage project. The district government is to allocate a 200 MW wind power quota in accordance with the requirements of higher-level government authorities, to provide energy supply support for the hydrogen energy network project that the Company plans to develop.

Second, in March 2026, Scage (Hong Kong) Limited, a subsidiary of the Company, acquired a 10% equity interest in Huangshan Tafu Intelligent Agricultural Machinery Equipment Co., Ltd., a company based in Huangshan, Anhui Province, that applies the Company's L4 intelligent drive-by-wire chassis and autonomous driving technology to electric tractors.

Third, the Company is in the process of developing an overseas supply-chain model under which core components are exported for local assembly rather than exporting complete vehicles. The Company intends to describe its operating structure and each of its business lines more fully in a subsequent press release.

Financial Reporting

The Company's fiscal year ended on June 30, 2026. Audited results for fiscal year 2026 will be reported in the Company's annual report on Form 20-F, which the Company expects to file within the period prescribed by applicable rules. All operating data contained in this release is unaudited and derived from the Company's internal records. The Company's most recently reported financial results, including revenue and profitability data for fiscal year 2025, are available in its annual report on Form 20-F. Results for the six months ended December 31, 2025, are available in its report on Form 6-K furnished on June 30, 2026.

Management Commentary

"Since listing, we have focused our resources on engineering, certification and delivering vehicles to customers. With 203 vehicles now delivered and a growing technology portfolio, we intend to report on our operations on a more regular basis. Going forward, we are committed to providing periodic operating updates so that shareholders have timely information about the Company," said Chao Gao, Chairman and Chief Executive Officer of Scage Future.

About Scage Future

Scage Future (Nasdaq: SCAG) is a Cayman Islands holding company whose operating subsidiaries develop and manufacture new energy heavy-duty commercial vehicles and e-fuel solutions. Headquartered in Nanjing, China, the Company's product portfolio spans battery electric, plug-in hybrid and hydrogen-electric heavy trucks for port, mining, long-haul logistics and agricultural applications, together with SOEC hydrogen production technology. For more information, visit ir.scagefd.com.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements. Such statements are made in reliance on the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.

Rihanna's Golden Dragon Gown has arrived: Guo Pei's Garden of Ethereal Realms Exhibition Opens at China National Silk Museum

HANGZHOU, China, Oct. 11, 2026 /PRNewswire/ -- The "Garden of Ethereal Realms: Guo Pei Costume Art Exhibition" opened on September 27, 2026, at the China National Silk Museum in Hangzhou. As a leading figure in Chinese contemporary haute couture, Guo Pei has spent four decades exploring the intersection of traditional craftsmanship and modern costume design. This exhibition is a personal retrospective that traces the evolution of her creative career.

Drawing from 40 years of work, the exhibition features approximately 200 haute couture pieces, organized into four sections and nine representative series. It systematically presents Guo Pei's long-term exploration of garment structure, traditional techniques, material language, and East-West aesthetics. Works on display include One Thousand and Two Nights, Legend, Samsara, Paradise Island, and Children's Dream, among others. Notably, the exhibition also showcases the golden embroidered dragon robe worn by global pop icon Rihanna at the 2015 Met Gala, red-carpet gowns for celebrated stars such as Liu Shishi and Dilraba, as well as costumes created for national stages including the Beijing Olympics and CCTV Spring Festival Gala.

The four sections—"Time, Fable, Rebirth," "Building Dreams, Legend," "Dream Isle Garden," and "Eastern Palace Echoes"—offer a comprehensive view of her artistic journey. A folded-paper installation is also featured, reinterpreting the contours, layers, and power of haute couture through structural language.

As a specialized museum dedicated to silk, textiles, and costume culture, the China National Silk Museum places haute couture within the context of silk history and dress culture. The exhibition invites the public to rediscover the contemporary value of traditional materials and craftsmanship, and to appreciate the time, skill, and creativity behind each haute couture piece.

Exhibition Information

Exhibition: Garden of Ethereal Realms: Guo Pei Costume Art Exhibition

Dates: September 27, 2026 – August 31, 2027

Location: Fashion Gallery, China National Silk Museum, Hangzhou

Content: 40 years of Guo Pei's creations, approximately 200 haute couture works

SOURCE China National Silk Museum

Share this article

Hargitay joined the U.S. Women's National Team as Purina's Honorary Captain to raise awareness and support for domestic violence survivors with pets during Domestic Violence Awareness Month

WASHINGTON, Oct. 11, 2026 /PRNewswire/ -- Purina, the Official Pet Care Partner of the U.S. Soccer Federation, brought its Purple Leash Project message and mission to the pitch during the U.S. Women's National Team match against Spain, presented by Purina, at Audi Field. Actress, producer and advocate Mariska Hargitay joined the pet care leader at the match to raise awareness of the issue of domestic violence, show support for survivors and inspire soccer fans to learn more about the Purple Leash Project and ways they can help survivors and their pets find safety together.

In recognition of Domestic Violence Awareness Month, Mariska Hargitay, a longtime Purina partner and dedicated champion for domestic violence survivors, joined Purina and the USWNT as Purina's Honorary Captain. Hargitay participated in the pre-match coin toss alongside Cassidy, a 75-pound Golden Retriever, and her handler, Patrice "Pat" Eller. Together, Cassidy and Pat are part of a Pet Partners pet therapy support team that provides comfort and reassurance to children who may be called to testify in court, helping create a greater sense of safety for children and families during difficult moments. Their work reflects the Purple Leash Project's focus on the healing power of comfort, connection and support for people and pets impacted by domestic violence.

The Purple Leash Project, a Purina initiative in partnership with nonprofit RedRover, helps domestic violence survivors and their pets escape abuse and heal together by making more shelters pet-friendly. Through grants to domestic violence shelters and social service providers, the initiative supports pet-friendly shelter renovations, on-site and off-site pet housing solutions, the purchase of essential pet supplies and the cost of necessary veterinary care, helping remove barriers to safety for survivors who might otherwise have to leave a beloved pet behind. Today, only 20% of domestic violence shelters allow pets, and 48% of survivors delay leaving an abusive situation because they cannot take their pets with them.

"Seeing the Purple Leash Project take the field helped turn the stadium into a powerful show of support for survivors and the pets they love," said Mariska Hargitay. "I'm honored to continue my work with Purina on a stage like this during Domestic Violence Awareness Month to bring greater awareness to domestic abuse, help break down the stigma survivors so often face and shine a light on the need for more safe, pet-friendly spaces where survivors and their beloved, trusted companions can begin healing together."

Bringing awareness to this important cause is a key way Purina works to support survivors, helping to erase the stigma many survivors encounter. Soccer fans can show their support for survivors and the Purple Leash Project by purchasing a limited-edition, Courageous & Comfy Soccer Scarf, officially licensed by U.S. Soccer and available exclusively at shop.PurpleLeashProject.com. One hundred percent of every purchase is a donation to RedRover to support the Purple Leash Project mission to help keep abuse survivors together with their pets.

"At Purina, we believe survivor safety shouldn't require sacrifice. That's why we're proud to continue our work with RedRover and grateful to Mariska for helping to bring greater visibility to the need for more safe spaces for domestic violence survivors on both ends of the leash," said Nina Leigh Krueger, CEO of Purina. "Together, we can help ensure survivors never have to choose between their safety and the safety of pets they love."

In addition to putting a spotlight on the Purple Leash Project, this game also reflected Purina's broader approach to sports collaborations, reimagining the role pets can play in sports culture, not only as companions at home, but as part of the fan experience itself. At Audi Field, Purina created the Purina Club, a temporary pet-friendly seating area where soccer fans can bring their dogs to cheer on the U.S. Women's National Team together. And, earlier this year, Purina launched its national "For the Team Behind the Team" campaign with U.S. Men's National Team player Weston McKennie and introduced the first national pet jersey for soccer fans and their pets. Purina also partnered with KC2026 on pet-centered programming at the FIFA Fan Festival Kansas City, including Dog Days, pet kits and adoption-focused community programming.

Through the Purple Leash Project, Purina has provided nearly 70 grants for more than $2.2 million across more than 30 states to help create pet-friendly spaces for domestic violence survivors and their pets. Purina is working toward an ambitious goal of helping to provide 1 million safe nights for survivors and their pets by the end of 2030.

Q: Why did Purina partner with the U.S. Women's National Team and Mariska Hargitay?

A: During Domestic Violence Awareness Month, Purina saw an opportunity to bring together two of its partners, the U.S. Soccer Federation and actress, producer and advocate Mariska Hargitay, to shine a light on the Purple Leash Project's efforts to support survivors with pets. The partnership aims to raise awareness of the dynamics of domestic violence, help reduce survivor stigma and highlight the importance of creating safe, pet-friendly spaces where survivors and their pets can escape abuse and heal together.

Q: What are the "Courageous Together" soccer scarves?

A: The "Courageous & Comfy" soccer scarves are limited-edition scarves created by Purina in partnership with U.S. Soccer to raise awareness for domestic violence survivors and their pets. They are available at shop.PurpleLeashProject.com, and 100% of every purchase is a donation to RedRover to help keep abuse survivors and their pets together.

Q: How can fans support the Purple Leash Project?

A: Fans can purchase a limited-edition "Courageous Together" soccer scarf at shop.PurpleLeashProject.com. One hundred percent of every purchase is donated to RedRover to support domestic violence survivors and their pets. Fans can also learn more about Purina's work through the Purple Leash Project at Purina.com/EscapeTogether.

Q: How is Purina expanding the role of pets in sports?

A: Purina is helping make pets part of the sports fan experience. Earlier this year, Purina launched the "For the Team Behind the Team" campaign with U.S. Men's National Team player Weston McKennie and introduced what it describes as the first national pet jersey for soccer fans and their pets. Purina also partnered with KC2026 on pet-centered programming at the FIFA Fan FestivalTM Kansas City, including Dog Days, pet kits and adoption-focused community programming.

About Nestlé Purina PetCare Nestlé Purina PetCare creates richer lives for pets and the people who love them. Founded in 1894, Purina has helped dogs and cats live longer, healthier lives by offering scientifically based nutritional innovations.

Purina manufactures some of the world's most trusted and popular pet care products, including Dog Chow, Purina ONE, Pro Plan, Friskies and Tidy Cats. Our more than 11,000 U.S. associates take pride in our trusted pet food, treat and litter brands that feed 46 million dogs and 68 million cats every year. Nearly 500 Purina scientists, veterinarians, and pet care experts ensure our commitment to unsurpassed quality and nutrition.

Over the past five years, Purina has contributed more than $150 million towards organizations that bring, and keep, people and pets together, as well as those that help our communities and environment thrive.

Purina is part of Nestlé, a global leader in Nutrition, Health and Wellness. For more information, visit purina.com or subscribe here to get the latest Purina news.

About RedRover Since 1987, RedRover has focused on bringing animals out of crisis and strengthening the human-animal bond through emergency sheltering, disaster relief services, financial assistance, and education. To learn how RedRover is creating a more compassionate world, visit RedRover.org.

About The U.S. Soccer Federation Founded in 1913, U.S. Soccer, a 501(c)(3) nonprofit, is the official governing body of the sport in the United States. Our vision is clear; we exist in service to soccer. Our ambition, working across the soccer ecosystem, is to ignite a national passion for the game. We believe soccer is more than a sport; it is a force for good. We are focused in three areas: Soccer Everywhere, ensuring everyone, everywhere experiences the joy of soccer; Soccer Success, our 27 National Teams and pro leagues winning on the world stage; and Soccer Investment, maximizing and diversifying investments to sustainably grow the game at all levels. For more information, visit ussoccer.com/ourvision.

Share this article

NEW YORK, Oct. 11, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Option Care Health, Inc. (NASDAQ: OPCH) related to its sale to an investor group comprised of affiliates of Clayton, Dubilier & Rice, LLC and McKesson Corporation. Under the terms of the proposed transaction, Option Care shareholders are expected to receive $32.05 in cash per share. Is it a fair deal?

Click here for more info https://monteverdelaw.com/case/option-care-health-inc/. It is free and there is no cost or obligation to you.

NOT ALL LAW FIRMS ARE EQUAL. Before you hire a law firm, you should talk to a lawyer and ask:

1. Do you file class actions and go to Court?

2. When was the last time you recovered money for shareholders?

3. What cases did you recover money in and how much?

About Monteverde & Associates PC

Our firm litigates and has recovered money for shareholders...and we do it from our offices in the Empire State Building. We are a national class action securities firm with a successful track record in trial and appellate courts, including the U.S. Supreme Court.

No one is above the law. If you own common stock in the above listed company and have concerns or wish to obtain additional information free of charge, please visit our website or contact Juan Monteverde, Esq. either via e-mail at [email protected] or by telephone at (212) 971-1341.

Contact:

Juan Monteverde, Esq.

MONTEVERDE & ASSOCIATES PC

The Empire State Building

350 Fifth Ave. Suite 4740

New York, NY 10118

United States of America

[email protected]

Tel: (212) 971-1341

Attorney Advertising. (C) 2026 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC (www.monteverdelaw.com). Prior results do not guarantee a similar outcome with respect to any future matter.

SOURCE Monteverde & Associates PC

Share this article

- New data show favorable outcomes with subcutaneous infliximab following intravenous infliximab interruption, regardless of prior antibody status, in adult patients with moderate to severely active Crohn's disease and ulcerative colitis

- Late-breaking analysis shows significantly higher rates of clinical remission and improved endoscopic outcomes with subcutaneous versus intravenous infliximab in patients with ileum-dominant Crohn's disease

JERSEY CITY, N.J., Oct. 11, 2026 /PRNewswire/ -- Celltrion USA, Inc. today announced that two analyses evaluating ZYMFENTRA® (infliximab-dyyb) will be presented in oral presentations on Oct. 13 and 14 at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting in Nashville, Tennessee. The data include a late-breaking pooled and propensity score-matched analysis comparing subcutaneous (SC) and intravenous (IV) infliximab in patients with ileum-dominant Crohn's disease, as well as a post hoc analysis from the Phase 3 LIBERTY-CD and LIBERTY-UC studies assessing the impact of prior anti-drug antibody (ADA) status on clinical outcomes following SC infliximab 240 mg initiation after interruption of IV infliximab treatment.[1,2]

"People living with inflammatory bowel disease (IBD) can have varied disease characteristics, presentations, and treatment histories that may shape a unique care pathway, and clinicians need evidence that reflects the range of patients they see," said Dr. Juby Jacob-Nara, Senior Vice President and Chief Medical Officer at Celltrion USA. "We're pleased to share new analyses at ACG that provide additional information about subcutaneous infliximab in Crohn's disease and ulcerative colitis and reflect Celltrion's commitment to advancing clinically meaningful research for the IBD community."

Presentation Details

Both analyses will be presented by Marla Dubinsky, M.D., Professor of Pediatrics and Director of the IBD Center at the Icahn School of Medicine, Mount Sinai, New York.

Post Hoc Analysis of LIBERTY-CD and -UC Studies Following an IV Infliximab Treatment Interruption

Date: Tuesday, Oct. 13, from 2:45-2:55 p.m. CT

Room: Karl F. Dean Grand Ballroom A, Level 4

Abstract Title: "Impact of Prior Anti-drug Antibody Status on Clinical Outcomes Following Subcutaneous Infliximab Initiation After Intravenous Infliximab Interruption: A Post Hoc Analysis of LIBERTY-CD and -UC Studies"

Session: Plenary Session 3A: IBD

Presentation: 40

A separate post hoc analysis evaluated efficacy, serum infliximab concentrations, and immunogenicity among patients from the placebo arms of the Phase 3 LIBERTY-CD and LIBERTY-UC studies who initiated SC infliximab 240 mg every two weeks following an interruption in IV infliximab treatment. Patients were assessed according to whether anti-drug antibodies (ADAs) had been detected before they began SC infliximab.[2]

Among patients who initiated SC infliximab 240 mg, 72.5% (37 of 51) of patients with Crohn's disease and 92.2% (71 of 77) of patients with ulcerative colitis had prior ADA positivity. The median interval between the last IV infliximab infusion and initiation of SC infliximab was 16 weeks in ADA-positive and ADA-negative patients in both the Crohn's disease and ulcerative colitis groups.[2]

Across Crohn's disease and ulcerative colitis populations, the analysis found clinical outcomes were generally similar regardless of whether patients had ADAs before starting SC infliximab, with clinical response in Crohn's disease and partial clinical response in ulcerative colitis observed by 8±2 weeks and sustained through 78 to 80 weeks. Serum infliximab concentrations increased after initiation of SC infliximab and were generally comparable over time across ADA-status groups. Levels of fecal calprotectin and C-reactive protein decreased at the first assessment after treatment began and remained lower through the final assessment. ADA positivity declined among patients with pre-existing ADAs, while new ADA development was uncommon in patients without prior ADAs.

"Anti-drug antibodies to intravenous infliximab can compromise infliximab reinitiation after treatment interruption. Data on subcutaneous infliximab initiation after a drug holiday are limited, particularly regarding the impact of prior ADA status on clinical outcomes," said Marla Dubinsky, M.D., Professor of Pediatrics and Director of the IBD Center at the Icahn School of Medicine, Mount Sinai, New York. "These post hoc findings suggest that prior ADA status did not appear to compromise clinical outcomes after initiating subcutaneous infliximab following drug holiday after intravenous infliximab induction."

Late-Breaking Data in Ileum-Dominant Crohn's Disease

Date: Wednesday, Oct. 14, from 9:30-9:40 a.m. CT.

Late-Breaking Abstract Title: "Comparative Efficacy of Subcutaneous Versus Intravenous Infliximab in Ileum-Dominant Crohn's Disease: A Pooled Analysis and Propensity Score-Matched Analysis of Infliximab Registrational Studies"

Session: Plenary Session 4B: Liver, Esophagus, CRC, IBD

Presentation: 72

The late-breaking abstract reports a pooled analysis of individual patient data from four infliximab registrational studies. The analysis included patients with ileal or ileocolonic Crohn's disease who received standard maintenance treatment with SC infliximab 120 mg every two weeks or IV infliximab 5 mg/kg every eight weeks. Of 884 patients across the studies, 200 met the eligibility criteria; a 1:1 propensity score-matched analysis included 70 patients in each treatment group.[1]

In the matched population at Week 54, patients receiving SC infliximab had higher rates of clinical remission, endoscopic response, and endoscopic remission than those receiving IV infliximab:[1]

- Clinical remission: 71.4% vs. 51.4% (P = 0.023)

- Endoscopic response: 65.7% vs. 27.1% (P 0.001)

- Endoscopic remission: 41.4% vs. 17.1% (P = 0.003)

The analysis also found that, in both treatment groups, endoscopic responders had significantly higher serum infliximab concentrations than nonresponders.

###

About ZYMFENTRA® (infliximab-dyyb; subcutaneous infliximab)

ZYMFENTRA® (infliximab-dyyb) is a prescription medicine used as an injection under the skin (subcutaneous injection) by adults for the maintenance treatment of moderately-to-severely active ulcerative colitis following treatment with an infliximab product given by intravenous infusion (IV), Moderately-to-severely active Crohn's disease following treatment with an infliximab product given by intravenous infusion (IV). ZYMFENTRA blocks the action of tumor necrosis factor-alpha (TNF-alpha), a protein that can be overproduced in response to certain diseases and cause the immune system to attack normal, healthy parts of the body.

ZYMFENTRA was approved by the FDA through the Biologics License Application (BLA) under the 351 (a) pathway of the Public Health Service Act (a "stand-alone" BLA). ZYMFENTRA is considered a new biologic with a first-approved subcutaneous administration form and thus will be under patent protection for its dosage form by 2037 and for its route of administration by 2040.

Indication and Important Safety Information

ZYMFENTRA® is a prescription medicine indicated in adults for maintenance treatment of:

Moderately-to-severely active Crohn's disease following treatment with an infliximab product administered intravenously.

Moderately-to-severely active ulcerative colitis following treatment with an infliximab product administered intravenously.

It is not known if ZYMFENTRA is safe and effective in children under 18 years of age.

What is the most important information I should know about ZYMFENTRA?

SERIOUS INFECTIONS

Patients treated with ZYMFENTRA are at increased risk for developing serious infections involving various organ systems and sites that may lead to hospitalization or death. Discontinue ZYMFENTRA if a patient develops a serious infection or sepsis.

Reported infections include:

- Active tuberculosis (TB), including reactivation of latent TB. Patients frequently presented with disseminated or extrapulmonary disease. Patients should be tested for latent TB before and during treatment with ZYMFENTRA. Treatment for latent infection should be initiated prior to treatment with ZYMFENTRA.

- Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients may present with disseminated, rather than localized, disease. Empiric anti-fungal therapy should be considered in patients at risk for invasive fungal infections who develop severe systemic illness.

- Bacterial, viral, and other infections due to opportunistic pathogens, including Legionella and Listeria.

The risks and benefits of treatment with ZYMFENTRA should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection. Closely monitor patients for the development of signs and symptoms of infection during and after treatment with ZYMFENTRA, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy.

Risk of infection may be higher in patients greater than 65 years of age, patients with comorbid conditions and/or patients taking concomitant immunosuppressant therapy. In clinical trials, other serious infections observed in patients treated with infliximab included arthritis bacterial, pneumonia, and urinary tract infection.

MALIGNANCIES

Malignancies, some fatal, have been reported in children, adolescents, and young adults treated with TNF blockers, including infliximab products.

Approximately half of these cases were lymphomas, including Hodgkin's and non-Hodgkin's lymphoma. The other cases represented a variety of malignancies, including rare malignancies that are usually associated with immunosuppression and malignancies that are not usually observed in children and adolescents. The malignancies occurred after a median of 30 months after the first dose of therapy.

New SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel Disease

- New Phase 3 AFFIRM data show higher rates of clinical and endoscopic response in Crohn's disease patients treated with subcutaneous SKYRIZI versus placebo across all efficacy endpoints and observed subgroups

- New open-label extension analyses demonstrate sustained endoscopic outcomes over time with SKYRIZI, even in patients with complex disease characteristics and prior treatment exposure

- In real-world studies, patients with advanced Crohn's disease achieved disease control with RINVOQ, highlighting its potential benefit for difficult-to-treat patients

- The breadth of scientific abstracts and oral presentations at the American College of Gastroenterology 2026 Annual Scientific Meeting demonstrates AbbVie's pursuit to address the complexities of inflammatory bowel disease care

NORTH CHICAGO, Ill., Oct. 11, 2026 /PRNewswire/ -- AbbVie today announced the presentation of 22 scientific abstracts from its market-leading inflammatory bowel disease (IBD) portfolio at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting in Nashville, Tennessee, Oct. 9-14. Data presented will include newly unveiled AFFIRM results showing efficacy for SKYRIZI® (risankizumab-rzaa) in advanced therapy-naïve Crohn's disease (CD) patients, open-label extension analyses demonstrating long-term outcomes with SKYRIZI in difficult-to-treat IBD and growing real-world evidence supporting RINVOQ® (upadacitinib) in advanced CD.

"People living with IBD want treatments that meaningfully reduce the burden of their disease," said Ryan DeMasi, M.D., vice president, global medical affairs, immunology, AbbVie. "Our presence at ACG reflects AbbVie's drive, as a leader in IBD, to provide what matters most to patients — therapies that perform over time and against the most complicated drivers of disease."

The ACG conference agenda is available here. Select AbbVie oral and poster presentations are highlighted below:

Clinical Remission and Endoscopic Outcomes With Subcutaneous SKYRIZI

Multiyear Endoscopic Healing With SKYRIZI in Patients With Complex Disease Characteristics and Prior Treatment Exposure

Remission and Endoscopic Response with RINVOQ for Advanced and Difficult-to-Treat Crohn's Disease

About SKYRIZI® (risankizumab-rzaa)

SKYRIZI is an interleukin-23 (IL-23) inhibitor that blocks IL-23 by selectively binding to its p19 subunit. IL-23, a cytokine involved in inflammatory processes, is thought to be linked to a number of chronic immune-mediated diseases.i SKYRIZI is approved by the U.S. Food and Drug Administration (FDA) for the treatment of moderately to severely active ulcerative colitis, plaque psoriasis, psoriatic arthritis and Crohn's disease.i 

On April 27, 2026, AbbVie announced submission of an application to the FDA seeking approval of SKYRIZI® for subcutaneous induction for the treatment of adult patients with moderately to severely active CD.

SKYRIZI® (risankizumab-rzaa) U.S. Uses and Important Safety Informationi

SKYRIZI is a prescription medicine used to treat:

- moderate to severe plaque psoriasis in adults and children 6 years of age and older who may benefit from taking injections or pills (systemic therapy) or treatment using ultraviolet or UV light (phototherapy).

- active psoriatic arthritis in adults and children 6 years of age and older.

- moderate to severe Crohn's disease in adults.

- moderate to severe ulcerative colitis in adults.

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about SKYRIZI® (risankizumab-rzaa)?

SKYRIZI is a prescription medicine that may cause serious side effects, including:

Serious allergic reactions:

- Stop using SKYRIZI and get emergency medical help right away if you get any of the following symptoms of a serious allergic reaction:

Infections:

SKYRIZI may lower the ability of your immune system to fight infections and may increase your risk of infections. Your healthcare provider should check you for infections and tuberculosis (TB) before starting treatment with SKYRIZI and may treat you for TB before you begin treatment with SKYRIZI if you have a history of TB or have active TB. Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with SKYRIZI.

- Tell your healthcare provider right away if you have an infection or have symptoms of an infection, including:

Do not use SKYRIZI if you are allergic to risankizumab-rzaa or any of the ingredients in SKYRIZI. See the Medication Guide or Consumer Brief Summary for a complete list of ingredients.

Before using SKYRIZI, tell your healthcare provider about all of your medical conditions,

including if you:

- have any of the conditions or symptoms listed in the section "What is the most important information I should know about SKYRIZI?"

- have an infection that does not go away or that keeps coming back.

- have TB or have been in close contact with someone with TB.

- have recently received or are scheduled to receive an immunization (vaccine). Medications that interact with the immune system may increase your risk of getting an infection after receiving live vaccines. You should avoid receiving live vaccines right before, during, or right after treatment with SKYRIZI. Tell your healthcare provider that you are taking SKYRIZI before receiving a vaccine.

- are pregnant or plan to become pregnant. It is not known if SKYRIZI can harm your unborn baby.

- are breastfeeding or plan to breastfeed. It is not known if SKYRIZI passes into your breast milk.

- become pregnant while taking SKYRIZI. You are encouraged to enroll in the Pregnancy Registry, which is used to collect information about the health of you and your baby. Talk to your healthcare provider or call 1-877-302-2161 to enroll in this registry.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of SKYRIZI?

SKYRIZI may cause serious side effects. See "What is the most important information I should know about SKYRIZI?"

Liver problems may happen while being treated for Crohn's disease or ulcerative colitis: A person with Crohn's disease who received SKYRIZI through a vein in the arm developed changes in liver blood tests with a rash that led to hospitalization. Your healthcare provider will do blood tests to check your liver before, during, and at least up to 12 weeks of treatment, and may stop treatment with SKYRIZI if you develop liver problems. Tell your healthcare provider right away if you notice any of the following symptoms: unexplained rash, nausea, vomiting, stomach (abdominal) pain, tiredness (fatigue), loss of appetite, yellowing of the skin and eyes (jaundice), and dark urine.

The most common side effects of SKYRIZI in people treated for Crohn's disease and ulcerative colitis include: upper respiratory infections, headache, joint pain, stomach (abdominal) pain, injection site reactions, low red blood cells (anemia), fever, back pain, urinary tract infection, and rash.

The most common side effects of SKYRIZI in people treated for plaque psoriasis and psoriatic arthritis include: upper respiratory infections, headache, feeling tired, injection site reactions, and fungal skin infections.

These are not all the possible side effects of SKYRIZI. Call your doctor for medical advice about side effects.

Use SKYRIZI exactly as your healthcare provider tells you to use it.

SKYRIZI (risankizumab-rzaa) is available in a 150 mg/mL prefilled syringe and pen, a 55 mg/0.37 mL prefilled syringe, a 600 mg/10 mL vial for intravenous infusion, and a 180 mg/1.2 mL or 360 mg/2.4 mL single-dose prefilled cartridge with on-body injector.

Please click here for the Full Prescribing Information and Medication Guide.

About RINVOQ® (upadacitinib)

Discovered and developed by AbbVie scientists, RINVOQ is a JAK inhibitor that is being studied in several immune-mediated inflammatory diseases. Based on enzymatic and cellular assays, RINVOQ demonstrated greater inhibitory potency for JAK-1 vs JAK-2, JAK-3 and TYK-2. The relevance of inhibition of specific JAK enzymes to therapeutic effectiveness and safety is not currently known.

Upadacitinib is being studied in Phase 3 clinical trials for alopecia areata, hidradenitis suppurativa, Takayasu arteritis, systemic lupus erythematosus and vitiligo. The use of upadacitinib for these diseases is not FDA approved, and its safety and efficacy have not been established for these diseases.

RINVOQ® (upadacitinib) U.S. Uses and Important Safety Informationii

RINVOQ is a prescription medicine used to treat:

- Adults with moderate to severe rheumatoid arthritis (RA) when 1 or more medicines called tumor necrosis factor (TNF) blockers have been used, and did not work well or could not be tolerated.

- Adults with active psoriatic arthritis (PsA) when 1 or more medicines called TNF blockers have been used, and did not work well or could not be tolerated.

- Adults with active ankylosing spondylitis (AS) when 1 or more medicines called TNF blockers have been used, and did not work well or could not be tolerated.

- Adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation when a TNF blocker medicine has been used, and did not work well or could not be tolerated.

- Adults with giant cell arteritis (GCA).

- Adults with moderate to severe ulcerative colitis (UC) when 1 or more medicines called TNF blockers have been used and did not work well or could not be tolerated, or after taking a different injection or pill (systemic therapy) when your healthcare provider does not recommend TNF blockers.